Literature DB >> 20416547

The role of azithromycin in patients with cystic fibrosis.

Abdullah A Yousef1, Adam Jaffe.   

Abstract

Interest in azithromycin in the management of patients with cystic fibrosis has grown over the last decade. Uniquely this drug has both antibacterial and immune modulating effects which appear to be the reason for its clinical benefit as proven in several well designed clinical studies. In this review we discuss the proposed mechanisms of action of azithromycin and review the evidence for its clinical effectiveness and safety in cystic fibrosis. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20416547     DOI： 10.1016/j.prrv.2009.12.003

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN： 1526-0542            Impact factor:   2.726


  14 in total

1.  Inflammation and Oxidation Biomarkers in Patients with Cystic Fibrosis: The Influence of Azithromycin.

Authors:  Casilda Olveira; Alicia Padilla; Antonio Dorado; Victoria Contreras; Eduardo Garcia-Fuentes; Elehazara Rubio-Martin; Nuria Porras; Esperanza Doña; Ana Carmona; Gabriel Olveira
Journal:  Eurasian J Med       Date:  2017-06

2.  Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge.

Authors:  V Balloy; A Deveaux; D Lebeaux; O Tabary; P le Rouzic; J M Ghigo; P F Busson; P Y Boëlle; J Guez Guez; U Hahn; A Clement; M Chignard; H Corvol; M Burnet; L Guillot
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 3.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

4.  Increased adherence to CFF practice guidelines for pulmonary medications correlates with improved FEV1.

Authors:  Brooke M Moore; Theresa A Laguna; Meixia Liu; John J McNamara
Journal:  Pediatr Pulmonol       Date:  2012-09-19

5.  Restoration of chloride efflux by azithromycin in airway epithelial cells of cystic fibrosis patients.

Authors:  Vinciane Saint-Criq; Carine Rebeyrol; Manon Ruffin; Telma Roque; Loïc Guillot; Jacky Jacquot; Annick Clement; Olivier Tabary
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

6.  An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.

Authors:  Martina Koeva; Alina D Gutu; Wesley Hebert; Jeffrey D Wager; Lael M Yonker; George A O'Toole; Frederick M Ausubel; Samuel M Moskowitz; Diane Joseph-McCarthy
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

7.  Azithromycin inhibits expression of the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aeruginosa.

Authors:  Isabel Pérez-Martínez; Dieter Haas
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

Review 8.  Fitting Pieces into the Puzzle of Pseudomonas aeruginosa Type III Secretion System Gene Expression.

Authors:  Emily A Williams McMackin; Louise Djapgne; Jodi M Corley; Timothy L Yahr
Journal:  J Bacteriol       Date:  2019-06-10       Impact factor: 3.490

Review 9.  Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.

Authors:  Niels Høiby
Journal:  BMC Med       Date:  2011-04-04       Impact factor: 8.775

10.  The role of macrolides in noncystic fibrosis bronchiectasis.

Authors:  Bruna de Campos Guimarães E Figueiredo; Cássio da Cunha Ibiapina
Journal:  Pulm Med       Date:  2011-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.